Healthcare Industry News: benign prostatic hyperplasia
News Release - March 1, 2006
HealthTronics Announces Exclusive Rights to Distribute BPH Surgical LaserAUSTIN, Texas--(HSMN NewsFeed)--March 1, 2006--HealthTronics, Inc. (NASDAQ:HTRN ), today announced that it has entered into an agreement to be the exclusive United States distributor for Revolix, an FDA approved, surgical laser device used for the treatment of benign prostatic hyperplasia (BPH).
Christopher B. Schneider, Urology Division COO, said, "The early response from our urology partners who have used this device has been extremely positive in comparison to the technology currently available. They like the front-end firing mode of the laser as well as other unique features not offered on other BPH laser devices. In addition to clinical benefits, we believe the economics of the Revolix are more favorable than those associated with the current BPH laser technology. The improved economics should benefit our physician partners and our growing prostate treatment business."
Kenneth Blunt, M.D., a urologist who is managing the introduction and clinical demonstrations for HealthTronics, stated, "The Revolix produces a wave length that is absorbed by water rather than hemoglobin which is believed to provide for more consistent vaporization as compared to a KTP type laser. Also, the Revolix is a continuous wave laser as opposed to the pulsed method of a holmium type laser which some believe is less efficient. This continuous wave is believed to create a cleaner, smoother application to the soft tissue or gland."
About HealthTronics, Inc.
HealthTronics provides healthcare services primarily to the Urology community and manufactures and distributes medical devices. The Company also manufactures specialty vehicles used for the transport of high-technology medical devices and broadcast & communications equipment. For more information, visit www.healthtronics.com.
Statements by the Company's management during the conference call announced in this press release that are not strictly historical, including statements regarding plans, objective and future financial performance, are "forward-looking" statements that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Although HealthTronics believes that the expectations reflected in such forward-looking statements are reasonable, no assurance can be given that the expectations will prove to be correct. Factors that could cause actual results to differ materially from HealthTronics' expectations include, among others, the existence of demand for and acceptance of HealthTronics' services, regulatory approvals, economic conditions, the impact of competition and pricing, financing efforts and other factors described from time to time in HealthTronics' periodic filings with the Securities and Exchange Commission.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.